Literature DB >> 22664973

Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Maya Balamane1, Vici Varghese, George L Melikian, W Jeffrey Fessel, David A Katzenstein, Robert W Shafer.   

Abstract

We created a panel of 10 representative multi-nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant recombinant infectious molecular HIV-1 clones to assist researchers studying NNRTI resistance or developing novel NNRTIs. The cloned viruses contain most of the major NNRTI resistance mutations and most of the significantly associated mutation pairs that we identified in two network analyses. Each virus in the panel has intermediate- or high-level resistance to all or three of the four most commonly used NNRTIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664973      PMCID: PMC3421573          DOI: 10.1128/AAC.00648-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Authors:  Laurence Rimsky; Johan Vingerhoets; Veerle Van Eygen; Joseph Eron; Bonaventura Clotet; Annemie Hoogstoel; Katia Boven; Gaston Picchio
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

2.  Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth Johnston; Kathryn M Dupnik; Matthew J Gonzales; Mark A Winters; Soo-Yon Rhee; Tomozumi Imamichi; Robert W Shafer
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

Review 3.  HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Authors:  Jade Ghosn; Marie-Laure Chaix; Constance Delaugerre
Journal:  AIDS Rev       Date:  2009 Jul-Sep       Impact factor: 2.500

4.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.

Authors:  Johan Vingerhoets; Lotke Tambuyzer; Hilde Azijn; Annemie Hoogstoel; Steven Nijs; Monika Peeters; Marie-Pierre de Béthune; Goedele De Smedt; Brian Woodfall; Gastón Picchio
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

6.  Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth C Reuman; Soo-Yon Rhee; Susan P Holmes; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2010-05-12       Impact factor: 5.790

7.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

8.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

9.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

Authors:  Soo-Yon Rhee; Tommy F Liu; Susan P Holmes; Robert W Shafer
Journal:  PLoS Comput Biol       Date:  2007-05       Impact factor: 4.475

View more
  11 in total

1.  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Authors:  George L Melikian; Soo-Yon Rhee; Vici Varghese; Danielle Porter; Kirsten White; Jonathan Taylor; William Towner; Paolo Troia; Jeffrey Burack; Edwin Dejesus; Gregory K Robbins; Kristin Razzeca; Ron Kagan; Tommy F Liu; W Jeffrey Fessel; Dennis Israelski; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2013-08-09       Impact factor: 5.790

2.  Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.

Authors:  Francesco Saladini; Alessia Giannini; Adele Boccuto; Ilaria Vicenti; Maurizio Zazzi
Journal:  J Clin Lab Anal       Date:  2017-03-17       Impact factor: 2.352

3.  Update of the drug resistance mutations in HIV-1: March 2013.

Authors:  Victoria A Johnson; Vincent Calvez; Huldrych F Gunthard; Roger Paredes; Deenan Pillay; Robert W Shafer; Annemarie M Wensing; Douglas D Richman
Journal:  Top Antivir Med       Date:  2013 Feb-Mar

4.  Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.

Authors:  William T Gray; Kathleen M Frey; Sarah B Laskey; Andrea C Mislak; Krasimir A Spasov; Won-Gil Lee; Mariela Bollini; Robert F Siliciano; William L Jorgensen; Karen S Anderson
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

5.  Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Dmitry S Belov; Pavel O Markov; Alexander V Kurkin; Andrea Altieri; Asim K Debnath
Journal:  J Med Chem       Date:  2020-02-17       Impact factor: 7.446

6.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

7.  Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Authors:  Duncan T Njenda; Shambhu G Aralaguppe; Kamalendra Singh; Rohit Rao; Anders Sönnerborg; Stefan G Sarafianos; Ujjwal Neogi
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

Review 8.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622

9.  Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors.

Authors:  Francesca Curreli; Shahad Ahmed; Sofia M Benedict Victor; Ildar R Iusupov; Evgeny A Spiridonov; Dmitry S Belov; Andrea Altieri; Alexander V Kurkin; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2021-01-08       Impact factor: 3.641

10.  In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.

Authors:  Francesco Saladini; Federica Giammarino; Behnaz A Hosseini; Alessia Giannini; Adele Boccuto; Filippo Dragoni; Ilaria Vicenti; Robert W Shafer; Maurizio Zazzi
Journal:  J Antimicrob Chemother       Date:  2021-01-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.